An Update Comprehensive Review On The Status Of Covid-19: Vaccines, Drugs, Variants And Neurological Symptoms

Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratorytract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have beendeveloped and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variantsof the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurologicalmanifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescentplasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratorytract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccinesthat have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and itscorrelation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs,and action against emerging viral mutant variants is needed.